Market Research Future

CA 125 Test Market to Observe Strong Development by 2023; Predicted MRFR Experts

CA 125 Test Market Information: By Devices (Spectrometer, Analyzer, Sample Collection Tube, Otopic Labeled Peptides), Indication (Cancer, Uterine Fibroid, Endometriosis), By End User - Global Forecast till 2023


Pune, India -- (SBWIRE) -- 02/06/2018 -- The global CA 125 Test Market is blooming and is expected to grow at a CAGR of 5.7% during the forecast period.

Cancer Antigen (CA) test is used to diagnose various disease such as cancer, uterine fibroids, endometriosis, and liver disease. CA 125 is a protein that is found in the blood. The test is mostly widely used of the diagnosis of ovarian cancer in women. Normal levels of CA 125 in the blood is less 30 units per ml. and elevated levels for CA 125 signals the presence cancer in the ovary. Besides diagnosis, the CA 125 test is also used for monitoring ovarian cancer, as well as for screening ovarian cancer in women suspected to be at high risk for developing the disease.

Increasing demand for cancer diagnosis and treatment services, rising prevalence of cancer among the women and increasing emphasis on women healthcare. Furthermore, extensive diagnostic tests for cancer, also fuel the market growth. The growth of the market is restrained by the high cost of devices used in cancer diagnostics.

Get a Sample Copy @ .

According to the American Cancer Society, in 2015, ovarian cancer represents only 3% of all malignancies in the U.S. women. Also there is a rise in the death rate due to various types of cancer of reproductive tract in women. Additionally, in the U.S., 22,280 women were estimated to have received an ovarian cancer diagnostic services and 14,240 deaths.

Key Players in the Global CA 125 Test Market

Some of the key players in this market are Allergan plc. (U.K), Amgen Inc. (U.S.), Bayer (Germany), BD (U.S.), Eli Lilly Company (U.S.) , Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Private Limited (Israel), AMAG Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Sanofi (France), Novartis (Germany), AbbVie Inc. (U.S.), GlaxoSmithKline plc. (U.S.), and others.

Regional Analysis of the Global CA 125 Test Market

America holds the first position in the market for CA 125 test owing to the rising prevalence of ovarian cancer in the U.S. and Canada. Additionally, the availability of a wide range of diagnosis and treatment methods for cancer and technological advancement in the field of oncology, also support the growth of the market in American countries. Presence of key player in the market also accelerates the growth of the market. These players are engaged in various strategic approaches such as mergers, acquisition, collaborations, partnership, and research activities, leading to the development of the market in North America.

Check Attractive Discount @ .

In Europe, the market shows extensive growth owing to extensive research and development activities, and increasing demand for new medical devices for diagnosis of cancer drive the growth of the market. Germany, U.K, and France acquire first, second and third place respectively, in the European CA 125 test market.

Brief TOC

Report Prologue
Market Introduction
Research Methodology
Market Dynamics
Market Factor Analysis
Global CA 125 test Market, by Device and Accessories
Global CA 125 test Market, by Indication
Global CA 125 test Market, by End User
Global CA 125 test Market, by Region
Company Landscape
Company Profiles
MRFR Conclusion

Ask to Expert @ .

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.